As of April 2023, the number of recruiting studies in the US was 24,138. Based on FDA data from new drug approvals in 2021, we can assume an average of 760 patients are needed…Continue Reading
What You Should Know:– H1, the connecting force for global healthcare provider, clinical, science, and research information, today announced the availability of indication-level diversity insights in addition to institution, provider, and patient diversity data…Continue Reading
As we dive right into 2023, medical affairs teams are at a turning point.
MSLs are no longer wasting valuable time waiting in line within the halls of ivory towers, trying to get face-time or…
The medical industry is far from achieving racial health equity, according to a new report from Accenture. But it could be. The report, which outlines some of the stark racial health disparities still plaguing…Continue Reading
It’s no secret that patient enrollment is one of clinical research’s biggest hurdles. According to an analysis of trials listed, 55% of terminated trials were ended because of low patient enrollment. The analysis also reported that Phase III and Phase IV trials have an enrollment efficiency of less than 40%. Yet another analysis found more than 80% of studies do not enroll on time, often leading to a study extension or additional research sites.
The problem isn’t just enrollment, it’s also the enrollment of diverse patients. Racial and ethnic minorities, specifically Black or African American, Hispanic/Latino, Indigenous and Native American, Asian, Native…